Literature DB >> 16942815

Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective.

Gina Bergström1, Ingvar Karlberg.   

Abstract

In this study, models for decentralization of responsibility for costs of subsidised outpatient prescription pharmaceuticals within the county councils in Sweden were studied. The aims of the decentralization were to cut the escalating costs associated with risk sharing mechanisms on a national level and to integrate utilization of drugs into the priority process in health care. History of development and the characteristics of the solutions on county level were identified, described and analysed from taped interviews with relevant persons in central management positions in the selected counties. Information was supplemented from documentation. Two main models were found, a population based model and a prescriber based. In the population based model, family medicine in primary care was responsible for subsidies of drugs classified as "basic" (80%) regardless of prescriber. In this model, hospital departments were responsible for the "special" drugs (20%) regardless of prescriber. In the prescriber based model each provider was responsible for costs of its own prescribing. We found that the prescriber based model was chosen for the strong incentives for cost containment, while the population based model was expected to focus more on service to patients. This reform was based on the assumption that incentives for cost containment on an organisational level are effective. Experiences from other reforms in health care support this hypothesis. This means that there is a risk that cost containment jeopardises medical decisions on patient level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16942815     DOI: 10.1016/j.healthpol.2006.07.006

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  5 in total

1.  Prescribing behaviour after the introduction of decentralized drug budgets: is there an association with employer and type of care facility?

Authors:  Karolina Andersson; Anders Carlsten; Tove Hedenrud
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

Review 2.  Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

Authors:  Björn Wettermark; Brian Godman; Karolina Andersson; Lars L Gustafsson; Alan Haycox; Vittorio Bertele
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Regional variation and adherence to guidelines for drug treatment of asthma.

Authors:  Marianne Heibert Arnlind; Björn Wettermark; Mika Nokela; Paul Hjemdahl; Clas Rehnberg; Eva Wikström Jonsson
Journal:  Eur J Clin Pharmacol       Date:  2009-10-14       Impact factor: 2.953

Review 4.  Pharmaceutical policies: effects of financial incentives for prescribers.

Authors:  Arash Rashidian; Amir-Houshang Omidvari; Yasaman Vali; Heidrun Sturm; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2015-08-04

5.  Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years.

Authors:  Karolina A Andersson; Max G Petzold; Peter Allebeck; Anders Carlsten
Journal:  BMC Health Serv Res       Date:  2008-02-29       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.